Hepatitis News : BMS’s Hep C Therapy Shows 94% Cure Rate in Hard-to-Treat Patients
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hep Newsletter
Join Us:

Back to home » Hepatitis News » November 2012


emailprint

November 16, 2012

BMS’s Hep C Therapy Shows 94% Cure Rate in Hard-to-Treat Patients

Bristol-Myers Squibb’s interferon-, ribavirin- and ritonavir-free triple combination hepatitis C virus (HCV) therapy showed a 94 percent cure rate in hard-to-treat patients, MedPage Today reports. The pharmaceutical company announced early results from its open-label, two-part Phase II study of three direct acting antivirals at the annual meeting of the American Association of the Study of Liver Disease (AASLD) in Boston. A previous study of HCV genotype-1-infected patients taking the agents daclatasvir, an NS5A replication complex inhibitor, and asunaprevir, an NS3 protease inhibitor, proved ineffective without pegylated-interferon and ribavirin (which are difficult to tolerate). So this study included BMS-791325, a non-nucleos(t)ide NS5B polymerase inhibitor, in hopes of achieving proof of both safety and significant antiviral activity with a triple therapy.

The drug regimen studied included once-a-day daclatasvir and twice-a-day asunaprevir and BMS-791325. Sixteen patients underwent 12 weeks of therapy, and another 16 participants took the regimen for 24 weeks. Three quarters of each study group had genotype 1a virus, which is the most difficult to treat, and the other quarter genotype 1b. Among the 12-week arm, 100 percent achieved undetectable viral load by the end of treatment, with 94 percent maintaining a sustained virologic response (SVR, considered a cure) 12 weeks after completing therapy. In the 24-week arm, 94 percent achieved an undetectable viral load by the end of treatment and an SVR four weeks later.  It is still too early for data on their SVR rates 12 weeks after therapy.  The combination therapy proved well tolerated, with no discontinuations due to side effects.


To read the MedPage Today article, click here.

To read the BMS release, click here.

Search: Hepatitis C virus, hep C, HCV, cure, sustained virologic response, SVR, MedPage Today, Bristol-Myers Squibb, American Association of the Study of Liver Disease , AASLD, Boston, daclatasvir, NS5A replication complex inhibitor, asunaprevir, NS3 protease inhibitor, pegylated-interferon, ribavirin, BMS-791325, non-nucleos(t)ide NS5B polymerase inhibitor, genotype-1, 1a, 1b, sustained virologic response, SVR, well tolerated.


Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
Current Issue
Forums
Poll
Blogs
Hep TV
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Should Medicaid limit access to new hep C drugs?
Yes
No


Survey
Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.